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Pharmacological Stimulation of Edar Signaling in the
Adult Enhances Sebaceous Gland Size and Function
Christine Kowalczyk-Quintas1, Sonia Schuepbach-Mallepell1, Laure Willen1, Terry K. Smith2,
Kenneth Huttner3, Neil Kirby3, Denis J. Headon4,5 and Pascal Schneider1,5
Impaired ectodysplasin A (EDA) receptor (EDAR) signaling affects ectodermally derived structures including teeth,
hair follicles, and cutaneous glands. The X-linked hypohidrotic ectodermal dysplasia (XLHED), resulting from EDA
deficiency, can be rescued with lifelong benefits in animal models by stimulation of ectodermal appendage
development with EDAR agonists. Treatments initiated later in the developmental period restore progressively
fewer of the affected structures. It is unknown whether EDAR stimulation in adults with XLHED might have
beneficial effects. In adult Eda mutant mice treated for several weeks with agonist anti-EDAR antibodies, we find
that sebaceous gland size and function can be restored to wild-type levels. This effect is maintained upon chronic
treatment but reverses slowly upon cessation of treatment. Sebaceous glands in all skin regions respond to
treatment, although to varying degrees, and this is accompanied in both Eda mutant and wild-type mice by
sebum secretion to levels higher than those observed in untreated controls. Edar is expressed at the periphery of
the glands, suggesting a direct homeostatic effect of Edar stimulation on the sebaceous gland. Sebaceous gland
size and sebum production may serve as biomarkers for EDAR stimulation, and EDAR agonists may improve skin
dryness and eczema frequently observed in XLHED.
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INTRODUCTION
Hypohidrotic ectodermal dysplasia (HED) is a congenital
condition defined by reduced or absent development of teeth,
hair follicles, and cutaneous glands, notably the eccrine sweat
glands (Clarke, 1987; Clarke et al., 1987; Wright et al., 1993).
This condition is caused by defects in signaling from the
transmembrane receptor, ectodysplasin A (EDA) receptor
(EDAR), most commonly because of mutation of the gene
encoding its ligand EDA that lies on the X chromosome (Kere
et al., 1996), or caused by mutation of the EDAR gene itself
(Monreal et al., 1999) or affecting its intracellular adapter
protein EDARADD (Headon et al., 2001). Absence or reduced
function of this tumor necrosis factor–like pathway leads to
failure to activate NF-kB that is required for initiation of
appendage development and control of morphogenesis
(Doffinger et al., 2001; Schmidt-Ullrich et al., 2001).
Most individuals with HED are males with the X-linked form
(XLHED), caused by mutation of the EDA gene. Although few
systematic reports of HED incidence exist, a recent Danish
study estimated the frequency of XLHED between 1.6 and
21.9 per 100,000 population, depending on the stringency of
diagnostic criteria applied (Nguyen-Nielsen et al., 2013).
Much of the ongoing management of XLHED-affected
patients centers on ameliorating the symptoms of glandular
dysfunction in the skin and mucosae. This management
includes provision of lubrication to the eyes to compensate
for reduction of Meibomian and lacrimal gland secretions
(Reed et al., 1970; Tyagi et al., 2011; Dietz et al., 2013),
administering artificial saliva due to xerostomia arising from
salivary gland reduction (Daniel et al., 2002), removal of nasal
and otic crusting (Callea et al., 2013), and application of
emollient to improve dry skin and eczema symptoms (Chen,
2006; Tyagi et al., 2011). External cooling during physical
exertion or in hot weather may also be needed because of
reduced or absent sweating (Hammersen et al., 2011;
Schneider et al., 2011).
Two types of pharmacological modulators of EDAR signal-
ing are currently available. The first consists of a modified
form of EDA containing its C-terminal tumor necrosis factor
domain fused to an Ig Fc domain (Gaide and Schneider, 2003)
and the second a set of mAbs that bind the EDAR extracellular
domain to stimulate this pathway (Kowalczyk et al., 2011),
presumably by causing clustering and activation of the
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receptor. Suppression of the EDA signal may be achieved by
blocking mAbs directed against the ligand’s receptor binding
domain (Kowalczyk-Quintas et al., 2014).
In the mouse, mutation of any of the Eda, Edar, or Edaradd
genes leads to a phenotype analogous to the human condition,
with defective development of teeth, glands, and certain types
of hair follicles (Srivastava et al., 1997; Headon and
Overbeek, 1999; Headon et al., 2001). The morphological
defects caused by Eda mutation can be rescued by prenatal or
perinatal administration of recombinant Fc-EDA protein
(Gaide and Schneider, 2003; Casal et al., 2007), or ligand
replacement using an EDAR agonist antibody (Kowalczyk
et al., 2011), as demonstrated in mouse and dog models of
XLHED. These therapeutic effects have lifelong benefit, but are
achieved only if ligand is administered during a developmental
window appropriate for a particular structure. Treatment after
the developmental window had no detectable effect on the
parameters examined. For example, shape of the first molar is
rescued only if Fc-EDA is administered to mice before
embryonic day 15 (Gaide and Schneider, 2003). Unknown,
however, is whether dynamic structures that undergo
continual cell proliferation might benefit from chronic EDAR
stimulation in adult life.
The sebaceous glands undergo constant cellular turnover
throughout life, driven by proliferation of the flattened cells at
the gland’s periphery. The daughter cells thus produced move
to the center of the gland, swelling as they accumulate and
modify lipids until cellular rupture and release of the sebum
into the hair canal or onto the skin surface (Niemann and
Horsley, 2012). The sebum itself is a complex lipid mixture
composed primarily of triglycerides, cholesterol, and wax
esters that act to aid skin barrier function and humidification
(Fluhr et al., 2003; Fluhr et al., 2008), modulate the skin
microflora (Fischer et al., 2014), deliver antioxidants to the
skin surface (Thiele et al., 1999), and maintain the hair
follicles (Zheng et al., 1999; Sundberg et al., 2000; Stenn,
2001). Altered sebaceous gland activity is implicated in the
pathogenesis of a number of dermatological conditions,
including acne vulgaris (Zouboulis et al., 2014), some forms
of dermatitis (Gary, 2013), and rosacea (Raghallaigh et al.,
2012), whereas reduced sebaceous function may be causative
in hidradenitis suppurativa (Kamp et al., 2011) and scarring
alopecia (Al-Zaid et al., 2011).
A characteristic of XLHED is that the sebaceous glands are
sparse and hypoplastic, this likely being the underlying cause
of the dry skin and susceptibility to eczema in this condition
(Reed et al., 1970; Daniel et al., 2002). In the EdaTa (Tabby
mutant) mouse model of XLHED the sebaceous glands are
reduced (Gruneberg, 1971), whereas constitutive expression
of an Eda transgene causes an increase in sebaceous gland
size (Cui et al., 2003; Mustonen et al., 2003). Cui et al. (2003)
have shown that persistent expression of Eda throughout
development and postnatal life leads to sebaceous gland
hyperplasia, but that subsequent suppression of Eda
expression in the adult is followed by sebaceous gland
reduction over a period of months. This demonstrates an
impact of Eda signaling on mature sebaceous gland function,
although whether this impact can be achieved when the Edar
pathway is activated for the first time in the adult, never
having been active during development, is unknown.
The generation of reagents that allow time-limited modula-
tion of EDAR activity at any stage of life (Gaide and Schneider,
2003; Kowalczyk et al., 2011; Kowalczyk-Quintas et al.,
2014), and the onset of clinical trials to assess the potential
of these medicines to treat XLHED and some forms of
autosomal HED, have prompted us to assess the responses
of adult sebaceous glands to activation of this pathway. We
find corrective effects at morphological and functional levels
upon Edar stimulation in adult XLHED animals, demonstrating
that at least some adult tissues retain an ability to respond
to chronic EDAR stimulation with potential therapeutic
benefit and also serving as a biomarker of EDAR stimulation
in vivo.
RESULTS
Rescue of sebaceous gland size in adult mice by treatment with
Edar-agonist antibody
We began by assessing whether sebaceous glands respond
to administration of the EDAR agonist mAb, mAbEDAR1
(Kowalczyk et al., 2011). EdaTa mice received intraperi-
toneal administrations of 2 mg kg1 mAbEDAR1 starting at
postnatal day 12, a time point when no developmental rescue
of hair, sweat glands, and teeth can be obtained (Gaide and
Schneider, 2003). Treatments were performed weekly for 24
weeks and tissue samples collected at 26 weeks of age,
together with skin from untreated EdaTa, from wild-type
mice, and from treated EdaTa mice in which treatment was
terminated 6 weeks before analysis to assess whether any
effect obtained would be reversible in this time period
(Figure 1a). Sebaceous gland size was determined in sections
of facial skin (Figure 1b) and measured to determine aggregate
gland size relative to skin length (Figure 1c). Untreated EdaTa
mutants had hypoplastic sebaceous glands, in aggregate
42-fold smaller than those of wild-type animals, whereas
systemic treatment of this mutant line with mAbEDAR1
completely rescued gland size. This rescue persisted for at
least 1 month after cessation of antibody administration. We
found that sebocyte size was unchanged across treatments and
genotypes (Figure 1d), indicating that reduced gland size in
EdaTa skin is due to a lack of sebocytes, rather than these cells
being smaller than normal. Rescue of sebaceous gland size by
mAbEDAR1 administration was thus achieved by increasing
cell number to that of wild-type mice.
Dynamics of sebaceous gland response to Edar stimulation
In order to obtain a dynamic view of sebaceous gland
responses to mAbEDAR1 administration and withdrawal, we
initiated treatment of EdaTa mutant and wild-type animals at
weaning (between 21 and 26 days of age, i.e., later than
postnatal day 12, and in the adult hair cycle, to further
exclude any contribution of developmental processes) with
2 mg kg 1 mAbEDAR1 and then either readministered every
second week until tissue collection or else maintained animals
with no further administration (Figure 2a). Untreated animals
were maintained as controls. We devised a more rapid
processing method to visualize sebaceous glands in ear skin:
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Figure 1. Edar stimulation in adult mice increases facial sebaceous gland size. (a) Schematic of experimental schedule using mAbEDAR1. Animal age is indicated
above. Gray color indicates no Edar stimulation. P12, postnatal day 12. (b) Hematoxylin and eosin (H&E)–stained sections of facial skin of untreated wild-type and
EdaTa mice, and of EdaTa mice continually treated for 5 or 6 months (mo.), with analysis at 6 months. Right panels show details of sebaceous glands (red dashed lines).
Glands are smaller in EdaTa than wild type. Both treatments rescue gland size. Scale bars¼100mm. (c) Quantification of sebaceous gland size on sectioned facial
tissues. (d) Quantification of sebocyte size as defined by number of nuclei per unit sebaceous gland area. This is unchanged by condition. Error bars indicate SD.
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collagenase was used to remove dermal tissue, followed by
staining for lipid using Oil Red O, a process that reveals
sebaceous glands as paired kidney-shaped structures around
the hair follicles (Figure 2b).
The average sebaceous gland size in ear skin was smaller in
EdaTa than in wild-type animals across the experimental time
course from 2 to 24 weeks after weaning (Figure 2c). Gland
sizes were relatively stable at different ages, with a trend to
reduced size in older individuals. Treatment with mAbEDAR1
produced no detectable effect on either EdaTa or wild-type
sebaceous glands after 2 weeks, but by 6 weeks an enlarge-
ment was detectable in EdaTa skin (Figure 2d). With 12 weeks
of continual treatment, involving 6 administrations in total, the
EdaTa glands had attained the size observed in wild type,
whereas treated wild-type animals displayed only a nonsigni-
ficant increase in gland size (Figure 2e). Similar effects were
observed in ear skin of EdaTa mice treated for 6 months with
mAbEDAR1 (Figure 1a, and data not shown). The effects of a
single administration to EdaTa were long-lived, being
detectable at the morphological level 12 weeks later, but lost
by 24 weeks (Figure 2d). Thus, despite this long-lived effect,
maintenance of sebaceous gland rescue requires chronic
treatment (Figure 2d).
Sebaceous glands in dorsal skin are highly responsive to Edar
stimulation
We next analyzed sebaceous glands in the more intensively
studied dorsal skin at the 12- and 24-week time points.
Aggregate sebaceous gland size in EdaTa skin was about half
that of wild type, but chronic treatment with mAbEDAR1
stimulated a large increase in the size of both mutant and
wild-type glands (Figure 3a and b). Similar to what was
observed in the ear, a single administration of mAbEDAR1
was less efficient than chronic treatment in increasing sebac-
eous gland size 12 or 24 weeks later (Figure 3b). The response
in dorsal skin appears less limited than in the ear skin as at the
12-week time point we measured 3.1-fold and 6.9-fold
increases for dorsal skin sebaceous glands of wild-type and
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Figure 2. Chronic Edar stimulation rescues EdaTa ear sebaceous glands. (a) Schematic of experimental schedule. Weeks since beginning of treatment are indicated
above. P21–P26, postnatal days 21 to 26. (b) Oil Red O staining of sebaceous glands in ear skin. Conditions as indicated. Scale bar¼ 250mm. Enlarged insets have
edge lengths of 250mm. (c) Sebaceous gland size in untreated EdaTa and wild type (WT). (d) Effects of mAbEDAR1 administration on sebaceous gland size of EdaTa
mice. Untreated gland sizes as in c. By 6 weeks after treatment, gland size is increased. Sustained treatment is required to achieve full rescue. (e) Effects of
mAbEDAR1 treatment on wild-type sebaceous glands. Untreated gland sizes are as in c. Adjacent data bars with no P-value indicate P40.05. Error bars indicate
SD. NS, not significant; wk., week. *Po0.05; **Po0.01; ***Po0.001.
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EdaTa mice (Figure 3b) compared with 1.4-fold and 2.3-fold
increases in ear skin sections (Figure 3c).
Edar expression in mature sebaceous glands
To identify the likely cellular target stimulated by mAbEDAR1,
we assessed which cell types in adult dorsal skin express the
Edar gene. In situ hybridization of adult mouse skin in anagen
phase revealed Edar expression at the periphery of the
sebaceous glands, but occasionally also on sebocytes in
wild-type animals but not in Edar-deleted (EdarOVE1B/OVE1B)
mice (Headon and Overbeek, 1999) (Figure 4a), suggesting
that antibody-driven sebaceous gland enlargement is achieved
by direct stimulation of the glands.
EDAR stimulation induces proliferation of sebocyte precursors
Cellular proliferation in EdaTa mice was analyzed by BrdU
incorporation and Ki67 immunostainings, both of which were
successful as witnessed by labeling of intestinal crypts, a site of
intense cell proliferation (Figure 4b). In skin, some BrdU-
positive and many Ki67-positive cells were detected in the
epidermis and in the pilosebaceous unit, in particular at the
periphery of sebaceous glands (Figure 4c) and in hair follicles
(data not shown). A single week of mAbEDAR1 treatment did
not significantly change gland size, but this difference was
obvious in mice treated for 3 weeks (Figure 4d). At 3 weeks,
both the number and percentage of Ki67-positive cells at the
periphery of sebaceous glands were higher in treated mice
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Figure 3. Chronic stimulation of Edar signaling greatly stimulates sebaceous gland enlargement in EdaTa and wild-type dorsal skin. (a) Hematoxylin and eosin –
stained tissue sections of dorsal skin of EdaTa and wild-type mice either untreated, treated once only at weaning, or treated every 14 days from weaning for 12
weeks. Insets show examples of sebaceous glands at higher magnification. Scale bars¼ 100mm. (b) Quantification of aggregate sebaceous gland size per unit
length of dorsal skin. (c) Same as in b, but for ear skin at 12 weeks processed in the same way. Error bars indicate SD. *Po0.05; **Po0.01; ***Po0.001.
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than in control (Figure 4d–f). Interestingly, in 4-week-old mice
(at 1 week of treatment), most cells at the periphery of
sebaceous glands were proliferating regardless of treatment.
These data suggest that the enlargement of sebaceous
glands observed after treatment is because of sustained
proliferation of sebocyte precursors at the periphery of sebac-
eous glands.
Functional enhancement of adult sebaceous gland activity by
Edar stimulation
We measured sebum output to determine whether morpholo-
gically enlarged glands can produce more sebum. Mice at
weaning were treated every second week with mAbEDAR1
that we have established here to increase sebaceous gland
size; mAbEDAR3, an independent Edar agonist mAb
(Kowalczyk et al., 2011), and Aprily2, a control isotype-
matched mAb (Schwaller et al., 2007) (Figure 5a). Mice
treated with Edar agonists had a disheveled and greasy
appearance (Figure 5b) that might be contributed to by
increased sebum production from the enlarged glands. Thin-
layer chromatographic analyses of sebum components
revealed that hair from treated mice carried more sebum than
that from control animals, this effect being particularly notable
in the wax diester fraction, but also significant in the faster and
slower migrating bands (Figure 5c and d). A morphological
increase in sebaceous gland size is thus accompanied by
increased sebum production. Effects were seen with anti-
EDAR antibodies but not with a control antibody, ruling out
nonspecific effects of mAb administration. At the 6-week time
point, untreated EdaTa mice had less sebum than wild-type
mice, but this difference was no longer observed 6 weeks later
(Figure 5e). In addition, there was consistently more sebum in
older mice (12- and 24-week time points) than in younger
ones (6 weeks), a difference that was still visible in treated
mice (Figure 5f). No significant differences were observed
between sebum of males and females. Analysis by electro-
spray mass spectrometry of three sebum samples per treatment
condition revealed, among other lipids, the presence of
lanosterol, cholesterol esters, wax monoesters (C42 to C50),
a major species of wax diester (C60), mostly saturated
triacylglycerols (and O-alkyl triacylglycerols) (C50 to C62),
and a prominent species of a polyunsaturated triacylglycerol
(C58) (Supplementary Figures S1 and S2 online, and data not
shown). Although treatment increased the amount of sebum,
in particular wax diesters, sebum components, and their fine
composition were remarkably similar between wild-type and
EdaTa mice, before and after treatment. One exception was the
polyunsaturated C58 triacylglycerol that was consistently
induced by treatment in wild-type but not in EdaTa mice
(Supplementary Figure S1 online, and data not shown).
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DISCUSSION
Ectodermal dysplasias in humans and in animal models are
identifiable in the early postnatal period because of impair-
ment of prenatal developmental processes. Rarely addressed is
the question of whether tissue homeostasis is also controlled
by EDAR pathway signaling, allowing a potential for ther-
apeutic effects of Edar agonists administered to HED patients
outside of the neonatal period. With the advent of reagents
allowing time-limited modulation of the EDAR pathway
(Kowalczyk-Quintas and Schneider, 2014), we can now
assess adult tissue responses to modulation of this pathway
and their kinetics. We report that adult sebaceous glands
respond to EDAR stimulation, with no apparent need for
developmental stimulation to achieve this response. Indeed, in
almost all cases the treated EdaTa glands attain the same size
as the treated wild-type glands. This homeostatic effect is slow
to appear and slow to revert, and chronic treatment is required
for maintenance. The half-life of mAbEDAR1 in mouse is
B11 days (Kowalczyk et al., 2011). Stability of the antibody
could explain the delayed reduction in size following
withdrawal, together with the cellular turnover rate of the
sebaceous gland itself. Although sebaceous glands in different
regions of the skin responded to Edar stimulation and
withdrawal in the same manner, the magnitude of changes
was different, with a relatively low limit on the amount of
enlargement seen in ear skin, whereas dorsal and facial skin
showed greater increases in gland size. These regional
differences in response may arise from differences in local
Eda, Edar, or Edaradd expression levels, or from the presence
of different numbers of progenitor cells that can respond to the
treatment in glands from different locations.
A number of Edar-responsive genes and processes acting
during early hair follicle development also influence adult
sebaceous gland function, potentially representing a single
molecular mechanism for Edar action in both developmental
and homeostatic situations. Sonic hedgehog expression is
stimulated by Edar activity in hair follicle placodes from
embryonic day 13 (Schmidt-Ullrich et al., 2006; Pummila
et al., 2007), and hedgehog signaling promotes sebaceous
gland development and hypertrophy (Allen et al., 2003). The
function of Edar signaling to suppress bone morphogenic
protein activity (Mou et al., 2006; Pummila et al., 2007) may
also be involved as bone morphogenic proteins are known
suppressors of sebaceous gland size (Plikus et al., 2004). As
Edar agonists stimulated proliferation in sebaceous glands
without increasing sebocyte size, increased proliferation of
sebaceous progenitor may represent the underlying mechanism
for glandular enlargement in these experiments. However, the
preferential stimulation of wax diester production in sebum
may additionally indicate a direct action of Edar signaling on
sebocytes. Whatever the mechanism, sebaceous gland res-
ponses can serve as a sensitive biomarker for EDAR pathway
stimulation in future clinical and experimental studies.
This report shows that chronic Edar stimulation in an animal
model of adult XLHED has corrective effects on at least one
gland type. The restoration of sebaceous function in XLHED
may improve the dry and eczematous skin frequently
observed in this condition (Reed et al., 1970; Daniel et al.,
2002; Chen, 2006; Tyagi et al., 2011). As chronic Edar
stimulation in both Eda-deficient and -proficient mice
boosted sebum output far above levels produced by
untreated wild-type mice, substantial improvement of sebum
production may be expected even in patients with reduced
numbers of sebaceous glands. EDAR pathway stimulation may
also stimulate growth and function of other glands affected by
XLHED, such as salivary and/or lacrimal glands (CKQ, SS, and
PS, unpublished preliminary observations), to perhaps achieve
functional benefit to dry eye and xerostomia. In addition,
although null mutations of EDA lead to absence of
Meibomian, eccrine, and tracheal glands, some cases of
XLHED likely involve hypomorphic mutations that allow
rudimentary glands to form during development. For
example, although Eda-deleted EdaTa mice lack sweat gland
structures entirely (Gruneberg, 1971; Gaide and Schneider,
2003), a substantial fraction of people with diagnosed XLHED
do have some sweat gland structures and a subset also have
low-level sweat production (Schneider et al., 2011). Edar
agonists may stimulate these glandular rudiments to increase
their function and possibly provide therapeutic benefit, as
observed here for hypoplastic sebaceous glands. Indeed, a
spectrum of EDA mutations of different severity, from null
mutations causing full XLHED syndrome to mutations causing
nonsyndromic tooth agenesis (Mues et al., 2009; Mues et al.,
2010), exist and also interact with modifier alleles in the
genetic background (Cluzeau et al., 2012). Thus, stimulation
of the Edar pathway in adult life may have benefit for XLHED
and for other conditions affecting cutaneous glands.
MATERIALS AND METHODS
Animals and antibody administration
Mice carrying the Tabby mutation (a deletion of the first exon and
promoter region of the Eda gene), and their wild-type controls were
derived from breeder pairs of B6CBACa-Aw-J/A-EdaTa/O mice
(000314; Jackson Laboratory, Bar Harbor, ME) (Gaide and
Schneider, 2003). EdaTa refers to both homozygous EdaTa/Ta females
and hemizygous EdaTa/Ymales. EdarOVE1B/OVE1B mice lacking all Edar
exons were as described previously (Headon and Overbeek, 1999).
Anti-EDAR mAbs mAbEDAR1 and mAbEDAR3 have been described
previously (Kowalczyk et al., 2011). Aprily-2, a mouse IgG1 directed
against human APRIL, was used as a control antibody (Schwaller
et al., 2007). Antibodies in sterile phosphate-buffered saline were
administered intraperitoneally at a dose of 2 mg kg 1. Mice were
handled according to Swiss Federal Veterinary Office guidelines
under the authorization of the Office Ve´te´rinaire Cantonal du
canton de Vaud (authorization 1370.5 to PS).
Tissue analyses and morphometrics
Hematoxylin and eosin–stained 8mm skin sections were imaged using
brightfield microscopy. Features on saved microscope images were
measured using ImagePro software (MediaCybernetics, Rockville,
MD). The area of sebaceous glands, identified by their characteristic
frothy appearance, was determined, summed for each image, and
normalized to the corresponding length of skin surface to obtain the
normalized aggregate gland area. At least four sections per animal
were measured to derive a mean gland size, and each section used
for measurement was at least 200mm away from any other.
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Outer and inner skins of ears were separated with forceps, washed
in Hank’s balanced salt solution and incubated for 2 hours in Hank’s
balanced salt solutionþ 5 mM CaCl2þ 1 mg ml 1 collagenase
(C2674; Sigma, Buchs, Switzerland) at 37 1C. Samples were then
washed in phosphate-buffered saline, fixed in 4% paraformaldehyde,
rinsed in 60% isopropanol, and stained in 0.5% Oil Red O in 60%
isopropanol. After washing with 60% isopropanol, samples were
stored in buffered formalin solution. Stereomicroscope images at the
outer and inner sides of the tip of the whole mount ear samples were
taken and the surface of 20 glands from each side of the ear was
measured using ImagePro (Rockville, MD). A mean value for each
side of the ear from each individual was calculated, and the mean of
the outer and inner sides calculated to give a value for that animal.
The mean ear sebaceous gland area and SD was calculated for groups
of mice in each treatment condition.
In situ hybridization
Dorsal skin of wild-type and EdarOVE1B/OVE1B adult mice, which had
been depilated 14 days earlier, was fixed in formaldehyde, dehy-
drated, and embedded in paraffin. Tissue sections of 5mm were cut,
deparaffinized, and processed for in situ hybridization and signal
detection using the RNAScope system according to the manufacturer’s
instructions (Advanced Cell Diagnostics, Hayward, CA) (Wang et al.,
2012). After color detection, sections were lightly counterstained with
hematoxylin and coverslipped using an aqueous mountant.
Analysis of cell proliferation
EdaTa mice (3 mice per group) were treated intraperitoneally at
weaning and 2 weeks later with mAbEDAR1 at 2 mg kg 1. At 2 hours
before killing (at 1 and 3 weeks after treatment initiation), mice were
given intraperitoneally BrdU at 40 mg kg 1 in phosphate-buffered
saline. Paraffin sections of back skin and small intestine were
immunostained with rat anti-BrdU (Gene Tex, Irvine, CA) and rabbit
anti-Ki67 (Abcam, Cambridge, UK) antibodies according to standard
procedures (Supplementary Materials and Methods online).
Sebum analysis
Hair was shaved off the dorsum, weighed (B70 mg), and sebum
extracted twice by adding 1 ml acetone each time. The pooled
acetone extracts were dried under nitrogen and sebum dissolved in
2ml of acetone per mg of dry hair. Of each sample, 6ml (equivalent to
the amount of sebum in 3 mg hair) was spotted on 20 5 cm high-
performance thin-layer chromatography silica plates, with 3mg of
cholesterol, 1.2mg of cholesterol oleate, and 6mg of rapeseed oil
(triglycerides) as standards. Plates were developed twice in toluene: n-
hexane (2:1, v/v), then dried, dipped in revelation solution (10% w/v
CuSO2.5H2O, 3.5% sulfuric acid, 3.1% phosphoric acid in methanol)
and heated at 140 1C until appearance of bands. The plate was then
photographed. Intensities of rapidly (including cholesterol esters and
wax monoesters), intermediate (wax diesters), and slowly (including
cholesterol and triglycerides) migrating bands were measured using
the ImageJ software (NIH, Bethesda, MD). Animals used for sebum
determination were a separate set from those used for measurement of
sebaceous gland size.
Statistics
Statistical analysis was performed with the Prism software (La Jolla,
CA) using unpaired t-test for the comparison of two samples and
analysis of variance with Newman–Keuls multiple comparison test for
multiple samples.
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